Over-accrual in Bayesian adaptive trials with continuous futility stopping

Author:

Barrado Leandro Garcia12ORCID,Burzykowski Tomasz123

Affiliation:

1. Data Science Institute and I-BioStat, Hasselt University, Hasselt, Belgium

2. International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium

3. Department of Biostatistics and Medical Informatics, Medical University of Bialystok, Bialystok, Poland

Abstract

Background:We explore frequentist operating characteristics of a Bayesian adaptive design that allows continuous early stopping for futility. In particular, we focus on the power versus sample size relationship when more patients are accrued than originally planned.Methods:We consider the case of a phase II single-arm study and a Bayesian phase II outcome-adaptive randomization design. For the former, analytical calculations are possible; for the latter, simulations are conducted.Results:Results for both cases show a decrease in power with an increasing sample size. It appears that this effect is due to the increasing cumulative probability of incorrectly stopping for futility.Conclusion:The increase in cumulative probability of incorrectly stopping for futility is related to the continuous nature of the early stopping, which increases the number of interim analyses with accrual. The issue can be addressed by, for instance, delaying the start of testing for futility, reducing the number of futility tests to be performed or by setting stricter criteria for concluding futility.

Funder

hercules foundation

Flemish Government – department EWI.

Publisher

SAGE Publications

Subject

Pharmacology,General Medicine

Reference21 articles.

1. Adaptive trial designs: a review of barriers and opportunities

2. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines

3. U.S. Food and Drug Administration. Adaptive design clinical trials for drugs and biologics guidance for industry, 2019, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry

4. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3